Skip to main content
Premium Trial:

Request an Annual Quote

Sue Pandey, Nancy Pecota, Gianfranco DeFeo, Linda Buck, Nanogen, Prodesse

Premium

People in the News

Sue Pandey has been named vice president of commercial operations at NuGen Technologies, the San Carlos, Calif.-based company said last week.

Pandey most recently served as global head of sales at GE Healthcare, where she was responsible for managing its CodeLink operation. Pandey holds a PhD in chemistry from the University of California, Irvine, and an MBA from Pepperdine University.

NuGen also named Nancy Pecota to the position of chief financial officer and Gianfranco DeFeo as the firm's new senior director of customer solutions.

Pecota previously served as vice president of finance and administration at Signature Bioscience and as a senior director of finance and accounting at Aclara BioSciences. She holds a BSc in economics from San Jose State University.

DeFeo previously worked at Applied Biosystems and Affymetrix. Most recently, he managed the global technical support organization at Quantum Dot. DeFeo holds a PhD from the University of California, Los Angeles.


DeCode Genetics named Linda Buck to its board of directors, the Reykjavik-Iceland based company said last week.

Buck received a Nobel Prize in physiology or medicine in 2004 for her discoveries on the workings of the olfactory system. She is the Associate Director of the Basic Sciences Division at the Fred Hutchinson Cancer Research Center in Seattle, Wash., and a Howard Hughes Medical Institute investigator. She also is an affiliate professor of physiology and biophysics at the University of Washington.

Prior to her current positions, Buck was a professor of neurobiology at Harvard Medical School and received her PhD in immunology from the University of Texas Southwestern Medical Center at Dallas.

 

New Product Watch

Nanogen this week launched two molecular reagent products to detect genetic sequences for respiratory viral pathogens.

The company now offers its NGEN RVA Analyte Specific Reagent product that it claims can be used to develop and validate assays to detect the sequences of and differentiates among influenza A and B, respiratory syncytial virus and parainfluenza 1, 2, and 3.

The RVA product was co-developed with Prodesse and has been CE marked in Europe, Nanogen said. It added that the ASR is "available in the United States as an ASR for which analytical and performance characteristics are not established."

Nanogen also launched its MGB Eclipse Flu A/B Primer and Probe Set, which it claims can provide melt curve analysis that enables differentiation of two viral strains for each sample tested.

The San Diego-based company also said both sets and reagents target a nucleic acid sequence also found in the H5N1 strain of the influenza A virus, also known as avian flu.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.